PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kotsiliti, E.* ; Leone, V. ; Schuehle, S.* ; Govaere, O.* ; Li, H.* ; Wolf, M.J.* ; Horvatic, H.* ; Bierwirth, S.* ; Hundertmark, J.* ; Inverso, D.* ; Zizmare, L.* ; Sarusi-Portuguez, A.* ; Gupta, R.* ; O'Connor, T.* ; Giannou, A.D.* ; Shiri, A.M.* ; Schlesinger, Y.* ; Beccaria, M.G.* ; Rennert, C.* ; Pfister, D.* ; Öllinger, R.* ; Gadjalova, I.* ; Ramadori, P.* ; Rahbari, M.* ; Rahbari, N.* ; Healy, M.E.* ; Fernández-Vaquero, M.* ; Yahoo, N.* ; Janzen, J.* ; Singh, I.* ; Fan, C.* ; Liu, X.* ; Rau, M.* ; Feuchtenberger, M.* ; Schwaneck, E.* ; Wallace, S.J.* ; Cockell, S.* ; Wilson-Kanamori, J.* ; Ramachandran, P.* ; Kho, C.* ; Kendall, T.J.* ; Leblond, A.L.* ; Keppler, S.J.* ; Bielecki, P.* ; Steiger, K.* ; Hofmann, M.* ; Rippe, K.* ; Zitzelsberger, H. ; Weber, A.* ; Malek, N.* ; Luedde, T.* ; Vucur, M.* ; Augustin, H.G.* ; Flavell, R.* ; Parnas, O.* ; Rad, R.* ; Pabst, O.* ; Henderson, N.C.* ; Huber, S.* ; Macpherson, A.* ; Knolle, P.* ; Claassen, M.* ; Geier, A.* ; Trautwein, C.* ; Unger, K. ; Elinav, E.* ; Waisman, A.* ; Abdullah, Z.* ; Haller, D.* ; Tacke, F.* ; Anstee, Q.M.* ; Heikenwälder, M.*

Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.

J. Hepatol. 79, 296-313 (2023)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND & AIMS: The progression of non-alcoholic steatohepatitis (NASH) to fibrosis and hepatocellular carcinoma (HCC) is aggravated by auto-aggressive T cells. The gut-liver axis contributes to NASH, but the mechanisms involved and the consequences for NASH-induced fibrosis and liver cancer remain unknown. We investigated the role of gastrointestinal B cells in the development of NASH, fibrosis and NASH-induced HCC. METHODS: C57BL/6J wild-type (WT), B cell-deficient and different immunoglobulin-deficient or transgenic mice were fed distinct NASH-inducing diets or standard chow for 6 or 12 months, whereafter NASH, fibrosis, and NASH-induced HCC were assessed and analysed. Specific pathogen-free/germ-free WT and μMT mice (containing B cells only in the gastrointestinal tract) were fed a choline-deficient high-fat diet, and treated with an anti-CD20 antibody, whereafter NASH and fibrosis were assessed. Tissue biopsy samples from patients with simple steatosis, NASH and cirrhosis were analysed to correlate the secretion of immunoglobulins to clinicopathological features. Flow cytometry, immunohistochemistry and single-cell RNA-sequencing analysis were performed in liver and gastrointestinal tissue to characterise immune cells in mice and humans. RESULTS: Activated intestinal B cells were increased in mouse and human NASH samples and licensed metabolic T-cell activation to induce NASH independently of antigen specificity and gut microbiota. Genetic or therapeutic depletion of systemic or gastrointestinal B cells prevented or reverted NASH and liver fibrosis. IgA secretion was necessary for fibrosis induction by activating CD11b+CCR2+F4/80+CD11c-FCGR1+ hepatic myeloid cells through an IgA-FcR signalling axis. Similarly, patients with NASH had increased numbers of activated intestinal B cells; additionally, we observed a positive correlation between IgA levels and activated FcRg+ hepatic myeloid cells, as well the extent of liver fibrosis. CONCLUSIONS: Intestinal B cells and the IgA-FcR signalling axis represent potential therapeutic targets for the treatment of NASH. IMPACT AND IMPLICATIONS: There is currently no effective treatment for non-alcoholic steatohepatitis (NASH), which is associated with a substantial healthcare burden and is a growing risk factor for hepatocellular carcinoma (HCC). We have previously shown that NASH is an auto-aggressive condition aggravated, amongst others, by T cells. Therefore, we hypothesized that B cells might have a role in disease induction and progression. Our present work highlights that B cells have a dual role in NASH pathogenesis, being implicated in the activation of auto-aggressive T cells and the development of fibrosis via activation of monocyte-derived macrophages by secreted immunoglobulins (e.g., IgA). Furthermore, we show that the absence of B cells prevented HCC development. B cell-intrinsic signalling pathways, secreted immunoglobulins, and interactions of B cells with other immune cells are potential targets for combinatorial NASH therapies against inflammation and fibrosis.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
25.700
0.000
5
3
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter B Cells ; Hcc ; Nafl ; Nafld ; Nash ; Fibrosis ; Gut-liver Axis; Fatty Liver-disease; Diet-induced Obesity; Nonalcoholic Steatohepatitis; Targeted Deletion; Immunoglobulin-a; Mouse Model; Mice; Promotes; Cancer; Syk
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 0168-8278
e-ISSN 1600-0641
Zeitschrift Journal of Hepatology
Quellenangaben Band: 79, Heft: 2, Seiten: 296-313 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Radarweg 29, 1043 Nx Amsterdam, Netherlands
Begutachtungsstatus Peer reviewed
Institut(e) Translational Metabolic Oncology (IDC-TMO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501000-001
Förderungen European Union
LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) project - European Union
Helmholtz Association's Initiative and Networking Fund
German-Israeli Helmholtz International Research School: Cancer-TRAX
Helmholtz Future topic Inflammation and Immunology
European Research Council (ERC)
HI-TRON
Helmholtz-Gemeinschaft, Zukunftsthema Immunology and Inflammation'
German-Israeli Cooperation in Cancer Research (DKFZ-MOST)
Deutsche Krebshilfe projects
Research Foundation Flanders (FWO)
Horizon 2020 grant (Hep-Car)
Rainer Hoenig Stiftung
Wilhelm Sander-Stiftung
ERC-CoG (HepatoMetaboPath)

EFPIA
Erich und Gertrud Roggenbuck Stiftung
Werner Otto Stiftung
Else Kroner Memorial Stipendium
European Respiratory Society/short term fellowship
DFG
Wellcome Trust Senior Research Fellowship in Clinical Science
Newcastle NIHR Biomedical Research Centre
Hamburger Krebsgesellschaft Stiftung
DOI 10.1016/j.jhep.2023.04.037
WOS ID 001044820600001
Scopus ID 85163564325
PubMed ID 37224925
Erfassungsdatum 2023-10-06
[➜Korrektur melden]